{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:30:21Z","timestamp":1790130621531,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Beh\u00e7et\u2019s disease (BD), a multisystemic inflammatory disorder with genetic predisposition, is frequently complicated by myelodysplastic syndrome (MDS), particularly in cases harboring trisomy 8. Patients with refractory BD-MDS exhibit poor responses to conventional therapies, including glucocorticoids and TNF-\u03b1 inhibitors, underscoring the need for novel therapeutic strategies. Janus kinase (JAK) inhibitors, which target cytokine-driven inflammation, represent a promising approach; however, clinical evidence in genetically complex BD-MDS cases remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a 29-year-old female with refractory intestinal BD, MDS, and dual trisomy 8\/9, who presented with recurrent ulcers, thrombocytopenia, and ileocolonic resection due to perforation. Despite sequential therapies (thalidomide, prednisolone, and infliximab), disease progression persisted. Initiation of upadacitinib (45 mg\/day), a selective JAK1 inhibitor, resulted in symptom resolution within one week and complete mucosal healing confirmed by colonoscopy at three months. Dose reduction to 15 mg\/day led to disease relapse, while maintenance at 30 mg\/day sustained remission over 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Immunohistochemical (IHC) analysis of intestinal specimens from the patient and three additional BD cases revealed robust phosphorylation of JAK1 and STAT3 in mucosal epithelium, stroma, and inflammatory infiltrates, particularly within occluded submucosal vessels. These findings mechanistically implicate JAK-STAT hyperactivation in BD-associated vascular pathology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights the efficacy of upadacitinib in managing refractory BD with MDS and dual trisomy 8\/9, a genetically complex phenotype. The dose-dependent response underscores the importance of tailored dosing strategies. Our mechanistic data further support JAK inhibition as a viable therapeutic alternative for TNF-\u03b1 inhibitor-resistant BD. These results warrant validation through randomized controlled trials to optimize therapeutic protocols for similar high-risk populations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1609884","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:23:21Z","timestamp":1748323401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Upadacitinib for refractory Beh\u00e7et\u2019s disease with myelodysplastic syndrome and trisomy 8\/9: a case report and mechanistic insights"],"prefix":"10.3389","volume":"16","author":[{"given":"Yukai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01226-7","article-title":"Beh\u00e7et\u2019s syndrome: recent advances to aid diagnosis","volume":"23","author":"Akbaba","year":"2023","journal-title":"Clin Exp Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03951-5","article-title":"How to treat myelodysplastic syndrome with clinical features resembling Beh\u00e7et syndrome: a\u00a0case-based systematic review","volume":"99","author":"Yilmaz","year":"2020","journal-title":"Ann Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403806","article-title":"Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution","volume":"19","author":"Bernasconi","year":"2005","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01868.x","article-title":"Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espa\u00f1ol de Citogen\u00e9tica Hematol\u00f3gica","volume":"108","author":"Sol\u00e9","year":"2000","journal-title":"Br J Haematol"},{"key":"B5","article-title":"The association of Beh\u00e7et\u2019s disease with myelodysplastic syndrome in Japan: a review of the literature","volume":"24","author":"Tada","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2023.0321","article-title":"Optimal treatment approaches to intestinal beh\u00e7et\u2019s disease complicated by myelodysplastic syndrome: the\u00a0KASID and KSBD multicenter study","volume":"65","author":"Park","year":"2024","journal-title":"Yonsei Med J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/04us5e","article-title":"Clinical features and independent predictors of Beh\u00e7et\u2019s disease associated with myelodysplastic syndrome","volume":"41","author":"Ding","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152039","article-title":"Clinical features and prognosis of patients with gastrointestinal Beh\u00e7et\u2019s disease-like syndrome and myelodysplastic syndrome with and without trisomy 8","volume":"55","author":"Liu","year":"2022","journal-title":"Semin Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2020.08.016","article-title":"Beh\u00e7et\u2019s-like syndrome and other dysimmunitary manifestations related to myelodysplastic syndromes with trisomy 8","volume":"42","author":"Wesner","year":"2021","journal-title":"Rev Med Interne"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.635663","article-title":"Contribution of janus-kinase\/signal transduction activator of transcription pathway in the pathogenesis of vasculitis: A possible treatment target in the upcoming future","volume":"12","author":"Bursi","year":"2021","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.610019","article-title":"Somatic\u00a0mutations and the risk of undifferentiated autoinflammatory disease in MDS: an under-recognized but prognostically important complication","volume":"12","author":"Watad","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.95","article-title":"Molecular mechanisms regulating NLRP3 inflammasome activation","volume":"13","author":"Jo","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00502","article-title":"Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment","volume":"7","author":"Kovtonyuk","year":"2016","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab513","article-title":"Somatic mutation in RUNX1 underlies mucocutaneus inflammatory manifestations","volume":"60","author":"Okano","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Behcet\u2019s syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000029189","article-title":"Extended-release tofacitinib for refractory\u00a0Beh\u00e7et disease: A case report","volume":"101","author":"Wang","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x221124014","article-title":"Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et\u2019s syndrome","volume":"14","author":"Zou","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981502","article-title":"Case report: Refractory intestinal Behcet\u2019s syndrome successfully treated with tofacitinib: A report of four cases","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/jgh.15997","article-title":"Gastrointestinal: Refractory parastomal ulcers of Behcet's disease responsive to tofacitinib","volume":"38","author":"Lin","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07089-x","article-title":"Clinical profiling, treatment characteristics and outcome in Behcet\u2019s Disease (BD)-A retrospective cohort study from Karnataka Rheumatology Association (KRA)","volume":"43","author":"Rao","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109241","article-title":"Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: A pilot study","volume":"247","author":"Liu","year":"2023","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109298","article-title":"Baricitinib for the treatment of refractory vascular Beh\u00e7et\u2019s disease","volume":"250","author":"Wang","year":"2023","journal-title":"Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.15275","article-title":"Case report: Peristomal pyoderma gangrenosum complicated by rheumatoid arthritis and Beh\u00e7et\u2019s disease successfully treated with baricitinib","volume":"27","author":"Ito","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with upadacitinib in two patients with anti-TNF-refractory macular edema associated with behcet\u2019s uveitis","volume":"32","author":"Tao","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1242","article-title":"Coexistence of ankylosing spondylitis and Behcet\u2019s disease: Successful treatment with upadacitinib","volume":"12","author":"Kraev","year":"2024","journal-title":"Immun Inflammation Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1439338","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA\u00a0network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1483993","article-title":"Case report: Successful\u00a0remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behcet\u2019s disease","volume":"15","author":"Sha","year":"2024","journal-title":"Front Immunol"},{"key":"B31","article-title":"Use of upadacitinib in refractory behcet\u2019s disease: case report and systematic literature review","volume":"24","author":"Patel","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-025-03874-x","article-title":"Targeting Janus kinase 1 in refractory Behcet\u2019s disease: a case report on the clinical efficacy of upadacitinib","author":"Ammoscato","year":"2025","journal-title":"Intern Emerg Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The\u00a0janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0168-9525(00)89000-9","article-title":"Jaks and Stats in signaling by the cytokine receptor\u00a0superfamily","volume":"11","author":"Ihle","year":"1995","journal-title":"Trends Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet\u2019s disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02695.x","article-title":"Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet\u2019s disease","volume":"139","author":"Imamura","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.80","article-title":"Type 17 T helper cells-origins, features and possible roles in rheumatic disease","volume":"5","author":"Annunziato","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"B40","article-title":"Th17 cells in Behcet\u2019s disease: a new immunoregulatory axis","volume":"29","author":"Hamzaoui","year":"2011","journal-title":"Clin\u00a0Exp Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.07.008","article-title":"Regulation of TH17 and regulatory T cells in patients with Behcet disease","volume":"128","author":"Direskeneli","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Behcet patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease","volume":"128","author":"Geri","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-013-1312-5","article-title":"Genetic variants in the JAK1 gene\u00a0confer higher risk of Behcet\u2019s disease with ocular involvement in Han Chinese","volume":"132","author":"Hou","year":"2013","journal-title":"Hum Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1089\/derm.2023.0058","article-title":"Efficacy and risk stratification of janus kinase inhibitors in the treatment of moderate-to-severe atopic dermatitis","volume":"35","author":"Narla","year":"2024","journal-title":"Dermatitis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089827","article-title":"Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Beh\u00e7et\u2019s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol","volume":"15","author":"Geertsema-Hoeve","year":"2025","journal-title":"BMJ Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:23:23Z","timestamp":1748323403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1609884"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1609884","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1609884"}}